IPO Radar: The latest IPO news
IPO Radar: Bally’s Casino, Republic Digital and Ant Group
Bally's Casino revises IPO on legal challenge, Republic Digital upsizes NASDAQ listing and Ant Group looks to Hong Kong.
IPO Radar: VERAXA, CATL and Zopa
IPO Radar: Klarna, Shein and MHA
Mumbai and Tokyo are driving the global IPO market
Blue Orca backs DN Auto’s machine tools IPO
IPO Radar: Newsmax, Aspargo Labs and Chime Financial
More IPO News
IPO Radar: Klarna, Stada and Quantum Base
Klarna files for NYSE IPO after return to profit, Stada postpones mega German listing, and Quantum Base is coming to AIM.
IPO Radar: CoreWeave, Hinge Health, Venture Global
CoreWeave cuts deal with Open AI ahead of anticipated IPO, Hinge Health files in New York and Venture Global craters.
IPO Radar: CoreWeave, Etihad Airways, Mixue
Excitement for tech investors as CoreWeave files for an IPO on Wall Street, while Etihad plans a major listing of 20% of stock.
IPO Radar: 7 Eleven, the biotech sector and Bally’s Chicago
Seven & i holdings in Japan considers IPO of US assets, biotech companies could be coming back to the market, and a Chicago casino.
European IPO market showing signs of a comeback, says PwC
Proceeds raised from European IPOs doubled in 2024 compared to 2023, thanks to Improving macroeconomic and equity market conditions.
IPO Radar: Canal+, NASDAQ’s bumper year and a Stegosaur
Canal+ debuts on the London Stock Exchange, Nasdaq listings market looking hot and Rally plans December IPO of a dinosaur.
SpectrumX: Could this be a winning biotech IPO prospect in 2025?
We take a closer look at Spectrum X, a UK biotech company which could list next year, and is currently taking on pre-IPO investment.
IPO Radar: Monzo, CoreWeave, Odyssey Therapeutics
Monzo CFO appointment sparks IPO expectations, CoreWeave aims for $35bn valuation in 2025 IPO, Odyssey Therapeutics meets investors pre-IPO.
IPO Radar: Talabat, Kioxia Holdings Corp, Groupe Dynamite
Delivery Hero plans to sell off some of its UAE subsidiary while Canadian women's fashion chain explores potential $1 billion IPO.
IPO Radar: Brazil Potash, K&F Growth Acquisition, Apotex, The GrowHub
Canadian miner Brazil Potash aims to get an IPO away in New York, while drug maker Apotex may test market next year.
IPO Radar: Septerna, Swiggy and Horizon Robotics
Biotech company Septerna is coming to NASDAQ, Swiggy cuts its IPO valuation and Hong Kong is back in business with Horizon Robotics IPO
IPO Radar: Lightmatter, Lulu Retail Holdings and Horizon Robotics
Our IPO round up this week features California-based tech firm Lightmatter, China's Horizon Robotics and UAE's Lulu Retail Holdings
Pulsar Helium IPOs on AIM
Pulsar Helium debuts on the AIM market to raise funds for its 'world-class' green helium project in Minnesota, USA
IPO Radar: EMEA IPO market wakes up, Springer Nature breaks Frankfurt drought
Elections in Europe over the summer months have caused a delay in many IPOs, but Springer Nature's Frankfurt listing may change things.
IPO Radar: MNTN, Jackson Acquisition II, OMS Group
Ryan Reynolds' ad company sits down with Morgan Stanley to talk IPO plans, while a $200m healthcare SPAC hits the market.
IPO Radar: GenIP, Hozon New Energy Automobile, Wealthsimple
Tekcapital to list AI specialist in the tech and recruitment space, while China's Hozon pushes ahead with Hong Kong IPO plans.
IPO Radar: Applied Nutrition, Zenas BioPharma, BingEx
Applied Nutrition said it would be seeking to float on the LSE main board at some time in the course of Q4.
IPO Radar: Kioxia, MBX Biosciences, Siguiri Gold
Japanese SSD maker Kioxia is relaunching its IPO bid in Tokyo after a four year hiatus, while MBX Biosciences files in the US.
IPO Radar: Tokyo Metro, Klarna Bank, MOH Nippon
This week we check out progress on major IPOs in the pipeline in Sweden and Japan, and there's an RTO onto the London market.
IPO Radar: Pershing Square, Cerebras Systems, Honor A-shares
Hedge fund manager Bill Ackman pulled his enormous $25bn NYSE IPO, while AI chipmaker Cerebras filed for a US IPO.
What are IPOs?
Initial Public Offerings (IPOs) mark the debut of a privately held company’s shares on the public stock market. This process offers an avenue for companies to raise capital by selling ownership stakes to the public. IPOs are significant events in the financial landscape, attracting both investor attention and market scrutiny.
The IPO process typically begins with a company selecting investment banks to underwrite the offering. These banks assist in determining the offering price, drafting the prospectus, and facilitating the sale of shares. The company’s financials, business model, and growth prospects are thoroughly scrutinized during this phase to assess its valuation and potential market reception.
For investors, IPOs present opportunities for early-stage investments in promising companies, potentially offering substantial returns if the company performs well post-listing. However, they also carry inherent risks, as the future performance of the company may not align with initial expectations. Investors must carefully evaluate the company’s fundamentals, market position, and growth prospects before participating in an IPO.
Companies often use IPO proceeds to fund expansion plans, repay debt, or provide liquidity to existing shareholders. The infusion of capital can fuel growth initiatives, such as research and development, acquisitions, or international expansion, enabling the company to scale its operations and capture market opportunities.
The IPO process involves regulatory compliance and transparency requirements to protect investors and ensure fair market practices. Companies must adhere to disclosure norms, providing detailed information about their financials, risks, and corporate governance practices to prospective investors.
Timing is crucial in the IPO journey, influenced by market conditions, industry trends, and investor sentiment. A favorable market environment can bolster demand for IPO shares, leading to successful offerings and strong aftermarket performance.
However, not all IPOs achieve immediate success. Market volatility, economic uncertainties, or mispricing can lead to lackluster debuts or even post-listing declines in share prices. Investors must adopt a long-term perspective, considering the company’s fundamentals and growth trajectory beyond the initial hype surrounding the IPO.
In summary, IPOs serve as vital milestones for companies seeking to access public capital markets and for investors looking to participate in the growth potential of emerging businesses. However, thorough due diligence and a cautious approach are essential for navigating the complexities and risks associated with IPO investing.
The Armchair Trader editorial team will keep you up to date with the biggest and most interesting IPO’s through our IPO news section. With an extensive network of contacts globally, we’ll bring you the latest IPO news from across the world, right here.